In September 2024, UCB and Biogen reported successful results from their Phase III clinical trial of the PHOENYCS GO study, which tested dapirolizumab pegol as a treatment for moderate-to-severe ...

These jobs will propel the province towards being a global leader in biomanufacturing and life sciences. MISSISSAUGA, ON, Nov ...

On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...

Turner, a seasoned biotechnology executive, was formerly CEO of Carmot Therapeutics, which was acquired by Roche in 2024 for $2.7 billion LB Pharma’s lead asset, LB-102, is a patent protected ...

Papadakis covers the Healthcare sector, focusing on stocks such as Sandoz Group Ltd, Zealand Pharma, and BioNTech SE. Roche Holding AG has an analyst consensus of Hold, with a price target consensus ...

Kennedy has been criticized for making false medical claims. He has also vowed to purge the U.S. Food and Drug Administration ...

It's not just vaccine makers that are down following the announcement that former President Donald Trump has nominated Robert ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

"Big Pharma" stocks took a tumble this morning following the news that President-elect Donald Trump has appointed Robert F.

Evotec, after stock-tanking blows, attracts private equity buyout interest: report Halozyme bought auto-injector specialist ...

Since the 2023 financing round, Flare’s lead program FX-909 has moved into a phase 1 clinical trial for patients with ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...